IBI351 + esomeprazole

IBI351 + esomeprazole is a combination therapy composed of IBI351 (also known as GFH925 or fulzerasib), an orally active, potent, selective, covalent and irreversible inhibitor of the KRAS G12C mutant protein, and esomeprazole, a proton pump inhibitor (PPI) that reduces gastric acid secretion. IBI351 is primarily being developed for cancers driven by KRAS G12C mutations, such as non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (CRC). Esomeprazole is widely used to treat acid-reflux disorders and gastrointestinal complications, potentially offering supportive care to reduce treatment-associated gastrointestinal symptoms. There is no direct clinical data identified for this specific combination; information is inferred from each component's mechanism and indications[2][3][4].